Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 194

1.

Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come.

van Besien KW, Orfali N.

J Clin Oncol. 2020 Mar 6:JCO2000177. doi: 10.1200/JCO.20.00177. [Epub ahead of print] No abstract available.

PMID:
32142395
2.

Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient.

Kodiyanplakkal RPL, Laplante JM, Westblade LF, van Besien K, Salvatore M, St George K.

Open Forum Infect Dis. 2019 Nov 18;6(12):ofz493. doi: 10.1093/ofid/ofz493. eCollection 2019 Dec.

3.

KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.

Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS.

Blood Adv. 2020 Feb 25;4(4):740-754. doi: 10.1182/bloodadvances.2019001053.

4.

Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts?

Orfali N, van Besien K.

Leuk Lymphoma. 2020 Apr;61(4):753-756. doi: 10.1080/10428194.2020.1725509. Epub 2020 Feb 12. No abstract available.

PMID:
32048529
5.

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK.

Blood Adv. 2020 Feb 11;4(3):560-572. doi: 10.1182/bloodadvances.2019000525.

6.

Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies.

Sfeir MM, Jiménez-Ortigosa C, Gamaletsou MN, Schuetz AN, Soave R, Besien KV, Small CB, Perlin DS, Walsh TJ.

J Fungi (Basel). 2020 Jan 31;6(1). pii: E20. doi: 10.3390/jof6010020.

7.

Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies.

Hsu J, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, Guarner D, Hsu YM, Cushing MM, Van Besien K.

Biol Blood Marrow Transplant. 2019 Dec 28. pii: S1083-8791(19)31734-3. doi: 10.1016/j.bbmt.2019.12.766. [Epub ahead of print]

PMID:
31891814
8.

Impact of a Multiplexed PCR Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients.

Rogers WS, Westblade LF, Soave R, Jenkins SG, van Besien K, Singh HK, Walsh TJ, Small CB, Shore T, Crawford CV, Satlin MJ.

Clin Infect Dis. 2019 Nov 5. pii: ciz1068. doi: 10.1093/cid/ciz1068. [Epub ahead of print]

PMID:
31687767
9.

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00047. Epub 2019 Sep 20.

10.

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.

Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Besien KV, Gaudet I, Law P, Kim NJ, Hofe EV, Jin MM.

Sci Rep. 2019 Jul 23;9(1):10634. doi: 10.1038/s41598-019-46938-7.

11.

Donor graft genotypes versus leukemia.

Choe HK, van Besien K.

Leuk Lymphoma. 2019 Jul;60(7):1606-1607. doi: 10.1080/10428194.2019.1613542. No abstract available.

PMID:
31238818
12.

Tocilizumab, in search for a role in acute GVHD.

Gergis U, van Besien K.

Leuk Lymphoma. 2019 Sep;60(9):2101-2103. doi: 10.1080/10428194.2019.1613545. Epub 2019 Jun 25.

PMID:
31238760
13.

Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.

van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO.

Blood Adv. 2019 Jun 25;3(12):1858-1867. doi: 10.1182/bloodadvances.2019000200.

14.

High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.

Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB.

Bone Marrow Transplant. 2019 Dec;54(12):2027-2038. doi: 10.1038/s41409-019-0587-0. Epub 2019 Jun 12.

PMID:
31190006
15.

It's not all about the CNS. High dose methotrexate in DLBCL.

Allan JN, Van Besien K.

Leuk Lymphoma. 2019 Aug;60(8):1845-1847. doi: 10.1080/10428194.2019.1613544. Epub 2019 May 23. No abstract available.

PMID:
31120336
16.

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S.

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18. No abstract available.

PMID:
30997845
17.

Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.

Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB.

Leuk Lymphoma. 2019 Jul;60(7):1693-1696. doi: 10.1080/10428194.2018.1543877. Epub 2019 Feb 10.

PMID:
30741059
18.

The application of precision medicine in diagnosing familial Mediterranean fever.

Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H.

Leuk Lymphoma. 2019 Aug;60(8):2091-2093. doi: 10.1080/10428194.2019.1571204. Epub 2019 Jan 30. No abstract available.

PMID:
30698071
19.

Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.

Choe H, Gergis U, Hsu J, Phillips A, Shore T, Christos P, van Besien K, Mayer S.

Biol Blood Marrow Transplant. 2019 Feb;25(2):e60-e64. doi: 10.1016/j.bbmt.2018.10.018. Epub 2018 Oct 26.

20.

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.

Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H.

Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019.

Supplemental Content

Loading ...
Support Center